ProCE Banner Activity

How I Sequence Recently Approved Immunotherapies in Advanced TNBC With vs Without BRCA Mutation

Clinical Thought
With sacituzumab govitecan, pembrolizumab, and atezolizumab all now approved for advanced TNBC, how do we sequence these agents and how does a BRCA1/2 mutation affect sequencing decisions? Here are my thoughts.

Released: December 23, 2020

Expiration: December 22, 2021

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS, has disclosed that his spouse/partner has ownership interest in and has received salary from Grail and that he has received consulting fees from Amgen, AstraZeneca, Eisai, Lilly, Merck, Novartis, Pfizer, and Seattle Genetics; and has received funds for research support paid to his institution from Acetylon, Amgen, Calithera, CytomX, Genentech/Roche, Immunomedics, Incyte, Lilly, Novartis, Pfizer, Seattle Genetics, and Zentalis.